New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
07:18 EDTMDT, COVMedtronic, Covidien deal tax implications complex, WSJ says
Medtronic (MDT) will be able to domicile in Ireland and gain a lower overall tax rate via its merger with Covidien (COV), but freeing Medtronic's future international earnings from U.S. taxes is complicated and will require additional steps, said The Wall Street Journal, citing tax experts. Reference Link
News For MDT;COV From The Last 14 Days
Check below for free stories on MDT;COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 28, 2014
07:05 EDTCOVCovidien acquires Sapheon, terms not disclosed
Covidien announced that it has acquired Sapheon, Inc., a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed.
August 27, 2014
11:41 EDTMDTMedtronic management to meet with Jefferies
Subscribe for More Information
10:05 EDTMDTMedtronic announces first implants in AdaptResponse CRT clinical trial
Medtronic announced the first implants in a clinical trial that will compare patient and healthcare system outcomes in heart failure patients who have cardiac resynchronization therapy devices with the AdaptivCRT feature enabled versus patients receiving standard CRT. The AdaptResponse trial will assess the superiority of the AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to patients' needs to customize therapy. It is expected to enroll approximately 3K patients worldwide. The primary endpoint of the AdaptResponse trial is a combination of all-cause mortality and the rate of medical intervention for worsening heart failure. The trial also will examine the incidence of atrial fibrillation in enrolled patients. Other secondary endpoints will assess patient quality of life measures as well as cost-effectiveness of CRT devices with the AdaptivCRT feature relative to standard CRT. Patients will receive a CRT-pacemaker or CRT-defibrillator equipped with the AdaptivCRT algorithm, and will be randomized 1:1 to either treatment or control groups. Patients will be followed at three and six months after randomization, and then every six months until trial closure.
05:40 EDTMDTMedtronic sees impact of NGC Medical acquisition neutral to FY15 earnings
Subscribe for More Information
August 26, 2014
19:33 EDTMDT, COVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 20, 2014
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
07:18 EDTCOV, MDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDT, COVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidienís TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use